openPR Logo
Press release

Lawsuit filed for Investors who lost money with shares of Cassava Sciences, Inc. (NASDAQ: SAVA)

A lawsuit was filed on behalf of investors in Cassava Sciences, Inc. (NASDAQ: SAVA) shares over alleged securities laws violations

A lawsuit was filed on behalf of investors in Cassava Sciences, Inc. (NASDAQ: SAVA) shares over alleged securities laws violations

An investor, who purchased shares of Cassava Sciences, Inc. (NASDAQ: SAVA), filed a lawsuit over alleged violations of Federal Securities Laws by Cassava Sciences, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Cassava Sciences, Inc. (NASDAQ: SAVA) have certain options and for certain investors are short and strict deadlines running. Deadline: February 10, 2025. NASDAQ: SAVA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Austin, TX based Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Cassava Sciences, Inc. reported that its annual Total Revenue rose from $80.02 million in 2022 to $105.95 million in 2023, and that its Net Loss increased from $76,24 million in 2022 to $97.21 million in 2023.

On November 25, 2024, Cassava Sciences, Inc. announced that its drug simufilam had failed to meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints in a Phase 3 study evaluating simufilam 100 mg tablets versus placebo over 52 weeks for the treatment of mild-to-moderate Alzheimer's disease ("AD"). In light of these disappointing results, Cassava also announced that it was discontinuing a second Phase 3 trial of simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks for the treatment of mild-to-moderate AD.

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) declined from $42.20 per share on August 05, 2024, to as low as $2.23 per share on December 20, 2024.

The plaintiff claims that between February 7, 2024 to November 24, 2024, the defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true capabilities of Cassava's drugs; notably, that Company simply did not have a drug that was capable of abating the progression of Alzheimer's Disease.

Those who purchased shares of Cassava Sciences, Inc. (NASDAQ: SAVA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Cassava Sciences, Inc. (NASDAQ: SAVA) here

News-ID: 3847669 • Views:

More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for long term investors in
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ: FTNT)
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on October 07, 2025
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR)
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Cassava

Global Cassava Starch And Pulp Market Size by Application, Type, and Geography: …
USA, New Jersey- According to Market Research Intellect, the global Cassava Starch And Pulp market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The cassava starch and pulp market is witnessing notable growth due to increasing demand across food, textile, paper, and pharmaceutical industries. Cassava, being
How to Start a Cassava Production Plant
Setting up a cassava processing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw material procurement, utility provisions, infrastructure setup, machinery and technology specifications, workforce planning, logistics, and financial considerations. IMARC Group's report titled "Cassava Processing Plant Project Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing a cassava processing
Cassava Starch Market: A Comprehensive Overview
Introduction Cassava starch is a vital product derived from the cassava plant, scientifically known as Manihot esculenta. This versatile starch is a key ingredient in various industries, including food and beverages, pharmaceuticals, textiles, paper production, and biofuels. With the growing demand for natural and gluten-free ingredients, cassava starch has become an essential component in many applications. Cassava, a root crop native to South America, has gained popularity worldwide due to its
Cassava Starch Market : An Overview
Introduction: Cassava starch, derived from the roots of the cassava plant, is a versatile product widely used in industries such as food and beverage, textiles, paper, and adhesives. Known for its thickening, stabilizing, and gelling properties, cassava starch has become a vital raw material in various industrial and commercial applications. Its cost-effectiveness and availability, particularly in tropical regions, make it a preferred choice over other starch sources such as corn and
Cassava Starch Market: A Comprehensive Overview
Introduction Cassava starch is a versatile and essential ingredient derived from the cassava root, widely used in various industries, including food and beverages, pharmaceuticals, textiles, and adhesives. Cassava, also known as manioc or yuca, is a tropical root crop native to South America but is now grown extensively in Asia, Africa, and Latin America. The starch extracted from cassava is prized for its neutral flavor, thickening properties, and ability to serve
Cassava Market Market Size, Growth Analysis 2031
We are excited to announce the release of our novel market research offering- "Cassava Market Size, Share and Trends | 2031". This syndicate research offers a present market scenario and includes future projections. Details such as the latest trends, technologies, and opportunities are certainly exclusive perks of this report. Both dominant market players as well as start-ups can purchase this market research. The Insight Partners added indispensable growth insights to help